Clinical trial
Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ…
NCT00297830 · Columbia University, Other · Completed
Key facts
| NCT number | NCT00297830 |
|---|---|
| Title | Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation |
| Official title | Zoledronic Acid Versus Alendronate for Prevention of Bone Loss After Organ Transplantation |
| Acronym | CTX |
| Lead sponsor | Columbia University, Other |
| Collaborators | Novartis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Heart Transplantation, Liver Transplantation, Bone Resorption |
| Intervention type | Drug, Other |
| Interventions | Zoledronic acid, Alendronate, Placebo Zoledronic Acid, Placebo Alendronate |
| Enrollment | 111 |
| Start date | Nov 1, 2005 |
| Primary completion | Apr 1, 2010 |
| Completion | Jan 1, 2014 |
| First posted | Mar 1, 2006 |
| Last update posted | Aug 16, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: